» Articles » PMID: 38473352

Epigenetic Mechanisms in Latent Epstein-Barr Virus Infection and Associated Cancers

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2024 Mar 13
PMID 38473352
Authors
Affiliations
Soon will be listed here.
Abstract

The Epstein-Barr Virus (EBV) is a double-stranded DNA-based human tumor virus that was first isolated in 1964 from lymphoma biopsies. Since its initial discovery, EBV has been identified as a major contributor to numerous cancers and chronic autoimmune disorders. The virus is particularly efficient at infecting B-cells but can also infect epithelial cells, utilizing an array of epigenetic strategies to establish long-term latent infection. The association with histone modifications, alteration of DNA methylation patterns in host and viral genomes, and microRNA targeting of host cell factors are core epigenetic strategies that drive interactions between host and virus, which are necessary for viral persistence and progression of EBV-associated diseases. Therefore, understanding epigenetic regulation and its role in post-entry viral dynamics is an elusive area of EBV research. Here, we present current outlooks of EBV epigenetic regulation as it pertains to viral interactions with its host during latent infection and its propensity to induce tumorigenesis. We review the important epigenetic regulators of EBV latency and explore how the strategies involved during latent infection drive differential epigenetic profiles and host-virus interactions in EBV-associated cancers.

Citing Articles

Histone Variant H2A.Z Cooperates with EBNA1 to Maintain Epstein-Barr Virus Latent Epigenome.

Castro-Munoz J, Maestri D, Yoon L, Karisetty B, Tempera I, Lieberman P bioRxiv. 2025; .

PMID: 39975074 PMC: 11838259. DOI: 10.1101/2025.01.28.635203.


Epigenetic and epitranscriptomic regulation during oncogenic -herpesvirus infection.

Singh R, Vangala R, Torne A, Bose D, Robertson E Front Microbiol. 2025; 15:1484455.

PMID: 39839102 PMC: 11747046. DOI: 10.3389/fmicb.2024.1484455.


Viral Oncogenesis: Synergistic Role of Genome Integration and Persistence.

La Frazia S, Pauciullo S, Zulian V, Garbuglia A Viruses. 2025; 16(12.

PMID: 39772271 PMC: 11728759. DOI: 10.3390/v16121965.


The 'Oma's of the Gammas-Cancerogenesis by γ-Herpesviruses.

Banerjee A, Dass D, Mukherjee S, Kaul M, Harshithkumar R, Bagchi P Viruses. 2025; 16(12.

PMID: 39772235 PMC: 11680331. DOI: 10.3390/v16121928.


The Functional Interaction Between Epstein-Barr Virus and MYC in the Pathogenesis of Burkitt Lymphoma.

Solares S, Leon J, Garcia-Gutierrez L Cancers (Basel). 2025; 16(24.

PMID: 39766110 PMC: 11674381. DOI: 10.3390/cancers16244212.


References
1.
Amoroso R, Fitzsimmons L, Thomas W, Kelly G, Rowe M, Bell A . Quantitative studies of Epstein-Barr virus-encoded microRNAs provide novel insights into their regulation. J Virol. 2010; 85(2):996-1010. PMC: 3020024. DOI: 10.1128/JVI.01528-10. View

2.
Mackett M, Arrand J . Recombinant vaccinia virus induces neutralising antibodies in rabbits against Epstein-Barr virus membrane antigen gp340. EMBO J. 1985; 4(12):3229-34. PMC: 554647. DOI: 10.1002/j.1460-2075.1985.tb04070.x. View

3.
Sears J, Ujihara M, Wong S, Ott C, Middeldorp J, Aiyar A . The amino terminus of Epstein-Barr Virus (EBV) nuclear antigen 1 contains AT hooks that facilitate the replication and partitioning of latent EBV genomes by tethering them to cellular chromosomes. J Virol. 2004; 78(21):11487-505. PMC: 523237. DOI: 10.1128/JVI.78.21.11487-11505.2004. View

4.
Patel P, Alghareeb R, Hussain A, Maheshwari M, Khalid N . The Association of Epstein-Barr Virus With Cancer. Cureus. 2022; 14(6):e26314. PMC: 9314235. DOI: 10.7759/cureus.26314. View

5.
Whittle H, Brown J, Marsh K, Greenwood B, Seidelin P, Tighe H . T-cell control of Epstein-Barr virus-infected B cells is lost during P. falciparum malaria. Nature. 1984; 312(5993):449-50. DOI: 10.1038/312449a0. View